• Something wrong with this record ?

Liver Organoids: Recent Developments, Limitations and Potential

SP. Harrison, SF. Baumgarten, R. Verma, O. Lunov, A. Dejneka, GJ. Sullivan

. 2021 ; 8 (-) : 574047. [pub] 20210505

Language English Country Switzerland

Document type Journal Article, Review

Liver cell types derived from induced pluripotent stem cells (iPSCs) share the potential to investigate development, toxicity, as well as genetic and infectious disease in ways currently limited by the availability of primary tissue. With the added advantage of patient specificity, which can play a role in all of these areas. Many iPSC differentiation protocols focus on 3 dimensional (3D) or organotypic differentiation, as these offer the advantage of more closely mimicking in vivo systems including; the formation of tissue like architecture and interactions/crosstalk between different cell types. Ultimately such models have the potential to be used clinically and either with or more aptly, in place of animal models. Along with the development of organotypic and micro-tissue models, there will be a need to co-develop imaging technologies to enable their visualization. A variety of liver models termed "organoids" have been reported in the literature ranging from simple spheres or cysts of a single cell type, usually hepatocytes, to those containing multiple cell types combined during the differentiation process such as hepatic stellate cells, endothelial cells, and mesenchymal cells, often leading to an improved hepatic phenotype. These allow specific functions or readouts to be examined such as drug metabolism, protein secretion or an improved phenotype, but because of their relative simplicity they lack the flexibility and general applicability of ex vivo tissue culture. In the liver field these are more often constructed rather than developed together organotypically as seen in other organoid models such as brain, kidney, lung and intestine. Having access to organotypic liver like surrogates containing multiple cell types with in vivo like interactions/architecture, would provide vastly improved models for disease, toxicity and drug development, combining disciplines such as microfluidic chip technology with organoids and ultimately paving the way to new therapies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017823
003      
CZ-PrNML
005      
20210729104035.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmed.2021.574047 $2 doi
035    __
$a (PubMed)34026769
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Harrison, Sean Philip $u Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Pediatric Research, Oslo University Hospital, Oslo, Norway
245    10
$a Liver Organoids: Recent Developments, Limitations and Potential / $c SP. Harrison, SF. Baumgarten, R. Verma, O. Lunov, A. Dejneka, GJ. Sullivan
520    9_
$a Liver cell types derived from induced pluripotent stem cells (iPSCs) share the potential to investigate development, toxicity, as well as genetic and infectious disease in ways currently limited by the availability of primary tissue. With the added advantage of patient specificity, which can play a role in all of these areas. Many iPSC differentiation protocols focus on 3 dimensional (3D) or organotypic differentiation, as these offer the advantage of more closely mimicking in vivo systems including; the formation of tissue like architecture and interactions/crosstalk between different cell types. Ultimately such models have the potential to be used clinically and either with or more aptly, in place of animal models. Along with the development of organotypic and micro-tissue models, there will be a need to co-develop imaging technologies to enable their visualization. A variety of liver models termed "organoids" have been reported in the literature ranging from simple spheres or cysts of a single cell type, usually hepatocytes, to those containing multiple cell types combined during the differentiation process such as hepatic stellate cells, endothelial cells, and mesenchymal cells, often leading to an improved hepatic phenotype. These allow specific functions or readouts to be examined such as drug metabolism, protein secretion or an improved phenotype, but because of their relative simplicity they lack the flexibility and general applicability of ex vivo tissue culture. In the liver field these are more often constructed rather than developed together organotypically as seen in other organoid models such as brain, kidney, lung and intestine. Having access to organotypic liver like surrogates containing multiple cell types with in vivo like interactions/architecture, would provide vastly improved models for disease, toxicity and drug development, combining disciplines such as microfluidic chip technology with organoids and ultimately paving the way to new therapies.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Baumgarten, Saphira Felicitas $u Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Pediatric Research, Oslo University Hospital, Oslo, Norway
700    1_
$a Verma, Rajneesh $u Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Pediatric Research, Oslo University Hospital, Oslo, Norway
700    1_
$a Lunov, Oleg $u Institute of Physics of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Dejneka, Alexandr $u Institute of Physics of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Sullivan, Gareth John $u Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Pediatric Research, Oslo University Hospital, Oslo, Norway $u Norwegian Center for Stem Cell Research, Oslo University Hospital, University of Oslo, Oslo, Norway $u Institute of Immunology, Oslo University Hospital, Oslo, Norway
773    0_
$w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 8, č. - (2021), s. 574047
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34026769 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104034 $b ABA008
999    __
$a ind $b bmc $g 1676431 $s 1138265
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 8 $c - $d 574047 $e 20210505 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
LZP    __
$a Pubmed-20210726

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...